|
|||||||
| Forum | Register | Calendar | Search | Today's Posts | Mark Forums Read |
![]() |
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
i really like this one and im looking for it to get hottt with poss news at close
|
|
|||
|
Ingen Enters Hospital and Therapy Markets With Expected Revenue Increase
CEO Live Radio Broadcast Talks About These New Markets YUCAIPA, Calif., Nov 20, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is now marketing direct to the hospital and therapy respiratory markets. Ingen's CEO, Scott Sand, will discuss these new markets this coming Tuesday, November 24, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley. According to the most recent report published in June 2009 and made available on the Global Market Research Information Network, respiratory market revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular. The company is introducing its new Oxyview Nasal Cannula at the America Association of Respiratory Care (AARC) on December 5 - 7, 2009 as an exhibitor. There are 47,000 members of AARC who are hospital based clinicians, therapists and managers, and a large majority will be attending this annual meeting in San Antonio, Texas. "Our focus has been home health care markets and this is going very smoothly with an increase in sales from home oxygen patients and oxygen providers. Our GSA application is expected to be approved in the near future, and with the growing hospital markets in respiratory care, the Oxyview Nasal Cannula will be an attractive device for hospital nursing as it has shown to save time and provide additional assurance of oxygen flow. Our near final ISO Certification expected in late December 2009 and our recent issue/publication of our patent in the People's Republic of China is in alignment with the future demand for our Oxyview Nasal Cannula in various export countries according to the most recent studies," stated Scott Sand, Chief Executive Officer and Chairman of the Board. World Respiratory Disorders Market 2009-2024 Welcome American Association for Respiratory Care MedOx Corporation - Welcome Ingen Technologies,Inc. - Home About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants, with issued patents in China and the USA, and pending patents in Japan, Canada and European Communities expected to be issued in 2010. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters. |
|
|||
|
IGNT: Ingen Technologies, Inc.
This stock is really taking off today!!! IMO this is a good one to keep on your radar folks!!! the chart is also looking really promising showing great signs of an upward swing for all investors!!! |
|
|||
|
--------------------------------------------------------------------------------
IGNT - Tradeing with high volume today!!! This is one to watch!!! RSI LINE approaching Bullish - Mac D running even This leading medical device manufacture that is focused on the $4B respiratory market with their oxyview products for the growing ageing population & emerging markets for home. A growing elderly popuulation increase in home oxygen therapy & surgeries, & an increase in chronic obstructive pulmonary dieseases in the USA has resulted in an increase of buyers for Ingen’s new Oxyview Nasal Cannula. Now provides models for adults, pediatrics & infants. The Oxyview Nasal Cannula is the only oxygen cannula in the world with a flow meter built-in that provides extremely accurate flow readings. |
|
|||
|
IGNT
Right now the is gap is 27 X 29 Bids are building @.0027 5 x 3 + 3.57 % recovering from the dip earlier today RSI LINE @ 46.97 and starting to rise HIST GRAM starting to build SLOPE is also starting to rise With IGNT entering the hospital and therapy markets I believe its only a matter of time before we see IGNT Take off , |
|
|||
|
Photo Release -- Ingen at Home Plate Ready to Catch Sales of $10M in 2010 and $50M in 2012
YUCAIPA, Calif., Nov 23, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that expected sales projections for 2010 and 2012 are on target. Photos accompanying this release are available at GlobeNewswire, Inc. and GlobeNewswire, Inc. The company's ISO Certification in December 2009 also allows Ingen to begin shipping product of its new Oxyview Nasal Cannula and Oxyview to China, Europe, Australia, Japan and Canada. Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M.The company's ISO consultant, Emergo Consulting Group, is assisting with both the ISO and CE Mark, as well as introducing these products to their distribution partners for export in these countries. In addition to ISO Certification, the company expects to have in place its GSA contract with various government sectors including VA Hospitals and the Department of Defense in 3-4 weeks. "Emergo Consulting Group will provide us with the outcome of the MEDICA exhibit in Germany, and this will be provided in a news release later this week. The Oxyview Nasal Cannula has received serious interest from institutional buyers, oxygen providers and suppliers, and patients. Sales have been made to all of these sectors in the past 2 months, and interest continues to grow," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board. Welcome U.S. Senior Population Projections by Age (2010-2050) - Bar Charts - Swivel COPD Statistics |
|
|||
|
Press Release on IGNT,
IGNT and Amsino International Sign Supply Agreement Click Here to Read the Featured Report about this Company YUCAIPA, Calif., Jan. 5, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News ), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that they have signed a Supply Agreement with Amsino International Inc. on December 1, 2009. The Pomona-California based Amsino was established in 1993 and is a leading medical device developer and manufacturer dedicated to advancing healthcare worldwide by developing, manufacturing, and marketing medical products that help improve the safety and effectiveness of patient care. Amsino's product and service portfolio includes infusion products and access devices, blood collection and transfusion devices, anesthesia and surgical products, urological products, enteral feeding and irrigation products, respiratory therapy products, patient care products, and a full-service contract manufacturing business. Amsino products are distributed in the United States and more than 30 other countries worldwide. Ingen and Amsino will manufacture the Oxyview and Oxyview Nasal Cannula at a reduced cost compared to current manufacturing costs. The Supply Agreement is effective for a 3-year term and is renewable. Ingen is ready for ISO 13485 Certification and is now waiting in line for an audit date in January-2010. The company expects to be certified and the CE Mark and distribution of product will follow. The company expects GSA approval and will make an announcement in January. Both ISO certification and GSA will expand product distribution to U.S. Government branches, inclusive of the Department of Defense and the VA Hospital network, as well as export to China, Japan, Canada, Australia and Europe. "We look forward to working with Richard Lee, CEO of Amsino, and his professional team. This agreement allows Ingen to reduce manufacturing costs by 40%, and increase efficiency and quality of our respiratory product line. Amsino International was introduced to us through Pacific Pearl Group, our Investment Banking consultants, who have evaluated Amsino as a good fit for manufacturing and distribution of the Ingen product line. With ISO certification near completion and GSA close to approval, the relationship between Amsino and Ingen is expected to be a prosperous one," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board. Watch the charts today, expecting a green finish! |
|
|||
|
Photo Release -- Ingen Launches the New Oxyview Pulse Oximeter
Another Giant Leap for Ingen YUCAIPA, Calif., Jan 6, 2010 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today the introduction of the new Oxyview Pulse Oximeter. A photo accompanying this release is available at GlobeNewswire, Inc. The Oxyview Pulse Oximeter is a very important and common device to check patient blood-oxygen saturation (SpO2) level and pulse rate. As a small, compact, simple, reliable and durable physiological monitoring device, the Oxyview Pulse Oximeter greatly enhances patient care, and fits both Adult and Pediatric patients. This small & lightweight design has a measurement range of 70% - 100%, and requires two AAA batteries. It has a Resolution of 1% with a measurement accuracy of 70% - 100%: +/- 3%. Some of the features include a dual color OLED display, display SpO2, PR, Pulse bar and Plethysmogram, 6 display modes, low power consumption, automatic power off, battery-low indicator, and an adjustable brightness feature. This dynamic new product is the most sophisticated and cost competitive pulse oximeter in the market today. The company is selling the new device for $88.00, and when patients purchase the Oxyview Nasal Cannula they will earn points and receive the new Oxyview Pulse Oximeter at a discount. The market for this device includes the home oxygen patient market and the hospital markets. "This new device will greatly enhance our revenues with expected sales of $1M in 2010, and increased sales with GSA contracts and our new distribution. The new Oxyview Pulse Oximeter has features that no other oximeter can offer, and the price is far less than that of any other Oximeter in its class," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board. Oxyview Nasal Cannula - Home - Yucaipa, CA Ingen Technologies,Inc. - Home About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters. The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc. (Photo: http://www.primezone.com/newsroom/prs/?pkgid=) |
|
|||
|
Ingen Introduces Oxyview Products at ATS
Effective Advertising and Product Branding Scheduled for 2010 Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes Symbol Price Change IGNT.PK 0.0023 0.0000 {"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Thursday January 14, 2010, 8:15 am YUCAIPA, Calif., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced the introduction of their Oxyview product line at the 2010 ATS International Conference on May 14-19, 2010 in New Orleans, Louisiana. The American Thoracic Society (ATS) is committed to disseminating the latest advances, nationally and internationally, in the fields of lung disease, sleep disorders and critical care medicine. The annual International Conference has become the premier, international forum for physicians and scientists who work in pulmonary, critical care, and sleep medicine. The company will reach 13,000 pulmonologists through the advertising in Medco Forum's ATS issue that is scheduled to be released on May 1, 2010. Medco Forum will also host the Oxyview advertising on their website. The company now advertises in several major publications, inclusive of COPD Digest, Today's Senior Magazine and Medco Forum. Throughout 2009, Ingen showcased their newest medical respiratory equipment at several conventions, including the MEDICA convention in Germany and the American Association of Respiratory Care (AARC) in San Antonio, Texas. These showings captured the attention of many distributors who were interested in Oxyview, taking Ingen a step closer to achieving international distribution and a growing presence in the hospital and therapy markets. As the number of respiratory diseases continue to increase, so too does the number of patients requiring oxygen support. That's why Ingen expects to see more demand for the Oxyview Nasal Cannula and the Oxyview Pulse Oximeter in 2010 and the coming years. The company expects to acquire more distributors in the United States and the developing markets of Asia, Canada, Australia and Europe. ATS 2010 * New Orleans Medco Forum Ingen Technologies,Inc. - Home About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters |
|
|||
|
IGNT Off to a slow start this morning. Stock is bearish right now but with this news that came out on the stock this morning I expect this stock to bounce back this afternoon and tmw. I also think today the stock will push through .25 and .26 today and see more apprecation tmw. I personally am playing this as a swing trade. Remember to do ur own research and this is strictly my opinion
|
![]() |
| Thread Tools | |
| Display Modes | |
All times are GMT. The time now is 05:54 AM.
ITalkCash.com - Forum for financial investments - Archive - Top
All rights reserved www.italkcash.com